Abstract
To compare the efficacy of sequential i.v. to p.o. moxifloxacin with ceftriaxone +/- azithromycin +/- metronidazole for the treatment of patients with community acquired pneumonia (CAP), a multi-centered, prospective, randomized, open label study was performed. CAP patients were randomized to moxifloxacin (400 mg/d-at least one i.v. dose) or ceftriaxone (at least one dose of 2 g i.v. q.d. followed by cefuroxime 500 mg p.o. b.i.d.) +/- azithromycin, +/- metronidazole (cephalosporin/macrolide control: CMC). The primary endpoint was clinical response at test-of-cure (TOC) visit. Bacteriological response at TOC was the secondary endpoint. Clinical cure was found in 83.3% (90/108) of moxifloxacin patients and 79.6% (90/113) of control patients. Microbiological responses were 81.8% (18/22) for moxifloxacin and 60.7% (17/28) for CMC patients. Drug-related adverse events occurred in 18.0% of moxifloxacin and 16% of CMC patients. It is concluded that i.v. to p.o. moxifloxacin is as effective as CMC for treatment of CAP and is a reliable alternative antimicrobial therapy.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Aged, 80 and over
-
Anti-Bacterial Agents / adverse effects
-
Anti-Bacterial Agents / therapeutic use
-
Aza Compounds / adverse effects
-
Aza Compounds / therapeutic use*
-
Azithromycin / adverse effects
-
Azithromycin / therapeutic use
-
Ceftriaxone / adverse effects
-
Ceftriaxone / therapeutic use
-
Community-Acquired Infections / drug therapy*
-
Community-Acquired Infections / ethnology
-
Constipation / chemically induced
-
Drug Therapy, Combination / adverse effects
-
Drug Therapy, Combination / therapeutic use*
-
Emergency Medical Services
-
Female
-
Fluoroquinolones
-
Humans
-
Male
-
Metronidazole / adverse effects
-
Metronidazole / therapeutic use
-
Middle Aged
-
Moxifloxacin
-
Nausea / chemically induced
-
Pneumonia, Bacterial / drug therapy*
-
Pneumonia, Bacterial / microbiology
-
Prospective Studies
-
Quinolines / adverse effects
-
Quinolines / therapeutic use*
-
Safety
-
Time Factors
-
Treatment Outcome
Substances
-
Anti-Bacterial Agents
-
Aza Compounds
-
Fluoroquinolones
-
Quinolines
-
Metronidazole
-
Ceftriaxone
-
Azithromycin
-
Moxifloxacin